Clinical Trial Update: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A [Phase 4]

View source ↗

Summary

Phase 4 open-label study assessing subcutaneous secukinumab in plaque psoriasis patients with inadequate response to cyclosporine A; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2017-06-27